Quotient Sciences and Acesion Pharma have collaborated, applying Quotient Sciences' Artificial Intelligence (AI)-enhanced formulation development solution within its Translational Pharmaceutics platform.

The collaboration supports Acesion's early-stage pipeline of small molecules targeted toward atrial fibrillation. It reflects both companies' shared commitment to advancing innovation in early drug development.

Quotient Sciences' AI- enhanced formulation development solution applies active Machine Learning (ML) with Bayesian optimisation to help identify and prioritise the drug products most likely to succeed in the clinic, enabling partners such as Acesion to make faster, better-informed decisions earlier in development.

The lifetime risk of developing atrial fibrillation is approximately 1 in 3 adults over age 55 years, making it one of the most common cardiovascular disorders associated with age.

Patients with atrial fibrillation face an approximately 5-fold increased risk of stroke, making effective management critical for reducing serious complications. Atrial fibrillation impacts an estimated 50-60 million people globally.

Dr. Andrew Lewis, Chief Scientific Officer, Quotient Sciences, said, "This collaboration with Acesion Pharma reflects exactly what our AI-enhanced formulation development solution, combined with Translational Pharmaceutics, is designed to deliver: helping our partners make better-informed, faster decisions about their drug product formulations. We're proud to be working with Acesion on a shared commitment to innovation, and to support their pipeline in the field of atrial fibrillation."

Quotient Sciences' Translational Pharmaceutics platform optimises drug development by integrating a range of drug product formulation and clinical activities. It has been used by biotech and pharmaceutical companies globally as a proven method for advancing candidates through early development for over 20 years.

Dr. Elisabeth V Carstensen, Vice President CMC,  Acesion Pharma, said, "We are excited to, together with Quotient Sciences, explore how their AI-enhanced algorithms can help guide and accelerate oral formulation development for our small-molecule compounds. By helping to guide and accelerate development decisions, this approach has the potential to shorten timelines for clinical testing and increase the likelihood of achieving the desired product profile."